Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Teva Parenterals Medicines, Inc.
WARNING LETTER
•Teva Parenterals Medicines, Inc.•July 24, 2009

Teva Parenterals Medicines, Inc. – FDA Warning Letter, Jul 24, 2009

Record Details

This Warning Letter, dated December 11, 2009, was issued to Teva Parenteral Medicines, Inc. following a July 13-24, 2009 inspection of their Irvine, CA facility. The inspection revealed significant violations of Current Good Manufacturing Practice (CGMP) Regulations for Finished Pharmaceuticals (21 CFR Parts 210 and 211), rendering their drug products adulterated.

Key violations include: 1. **Failure to test components for microbiological contamination:** Specifically, raw materials for Propofol Injectable Emulsion were not tested for bacterial endotoxin. 2. **Inadequate investigation of discrepancies:** The firm failed to identify root causes for out-of-specification endotoxin levels in Propofol lots, including a recalled lot, and did not adequately investigate water contamination in vials or chipped lip vials, failing to extend investigations to other potentially affected batches. 3. **Inadequate acceptance criteria for sampling:** The finished product sampling plan for Propofol was not statistically representative of batch sizes. 4. **Failure to test in-process materials:** In-process non-sterile bulk solution and end-of-run samples were not tested for bacterial endotoxin. 5. **Inadequate bacterial endotoxin test methods:** Deficiencies in vortexing, pH adjustment, and vibration protection for testing equipment were noted. 6. **Failure to demonstrate appropriate equipment design:** Validation of

Company
Teva Parenterals Medicines, Inc.
Inspection date
July 24, 2009
Product type
Drugs
Office
Los Angeles District Office
People
  • Alonza E. Cruse (Director)
  • William S. Vitale (Compliance Officer)
View Company Profile

ID · 40fca48a-5da4-45e5-a77d-f36f00621492

Violation Codes10
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 211FD&C Act 501(a)(2)(B)21 CFR 211.84(d)(6)21 CFR 211.19221 CFR 211.165(d)21 CFR 21I.110(c)21 CFR 211.165(b)21 CFR 211.63

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Teva Parenterals Medicines, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.